[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anaphylaxis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anaphylaxis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,43,79,107,136,165,185,210],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100577043","diagnosis-and-allergen-identification-of-perioperative-anaphylaxis-100577043",false,"NCT06793163","Diagnosis and Allergen Identification of Perioperative Anaphylaxis","Diagnosis and Allergen Identification of Perioperative Anaphylaxis: a Multicenter Prospective Cohort Study","Inclusion Criteria:\n\n* Aged 2 years or over;\n* Suspected anaphylaxis in the operating rooms, or history of suspected anaphylaxis in the operating room.\n\nExclusion Criteria:\n\n* Refuse to participate;\n* Other conditions that are considered unsuitable for study participation.","ALL","2 Years",{"count":19,"type":20},115,"ESTIMATED","OBSERVATIONAL","Perioperative anaphylaxis may lead to fatal respiratory and\u002For circulatory events, yet both clinical diagnosis and management are challenging. Serum tryptase is an indicator that can provide important retrospective diagnostic value for anaphylaxis. Another key point in perioperative anaphylaxis management is to identify the allergens, and thus avoid re-exposure during later perioperative management. Skin testing is an important way to identify allergens.",[24,25,26,27,28],"Perioperative\u002FPostoperative Complications","Anaphylaxis","Tryptase","Allergens","Skin Testing",[24,25,26,27,28],"RECRUITING","2026-06-16",{"date":33,"type":34},"2026-06-18","ACTUAL",{"date":36,"type":34},"2025-01-25",{"date":38,"type":20},"2027-12",{"name":40,"class":41},"Peking University First Hospital","OTHER",6,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100595922","phase-1-effects-of-inhaled-epinephrine-on-systemic-allergic-reactions-during-allergy-testing-immunotherapy-or-oral-challenges-100595922","NCT07038746","Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges","A Phase 1b, Open-Label, Exploratory Study Evaluating the Effects of Inhaled Epinephrine in Individuals Experiencing Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges","Inclusion Criteria:\n\n1. Males or females, aged ≥ 12 years with known or suspected allergen sensitivity who can also have a clinical history of immunoglobulin E (IgE)-mediated allergy, including a documented sensitivity to allergens (i.e., positive skin prick test, or positive in vitro serum IgE).\n2. Have undergone either a) allergy testing for suspected sensitivity\u002Fallergy, b) future oral challenge (food and\u002For drug) or future OIT to treat existing allergies or c) SCIT AND experienced a SAR Grade 2 or higher, following allergy testing, SCIT, or oral challenges (food and\u002For drug) for future OIT, and deemed eligible for enrollment by the Principal Investigator.\n3. For females of child-bearing potential, not pregnant or lactating, willing to use an acceptable contraception\\* method between Screening and End-of-Study Visits.\n\nExclusion Criteria:\n\n1. Known reaction or sensitivity to epinephrine or any of the ingredients of inhaled epinephrine.\n2. Known history or presence of clinically disease\u002Fcondition that could confound the results of the study or place the subject at undue or additional risk per the judgment of the Investigator.\n3. Abnormal vital signs at screening (i.e., systolic blood pressure: \\\u003C 90 or \\>140 mmHg, diastolic blood pressure: \\\u003C 40 or \\> 90 mmHg or, heart rate: \\\u003C 45 or \\> 100 bpm), respiration rate \\\u003C 8 or \\> 20 resp.\u002Fmin.\n4. Females who are pregnant, plan to become pregnant or lactating.\n5. Participation in another clinical study involving an investigational drug within 30 days prior to screening, an investigational biologic within 60 days prior to screening, or current\u002Fplanned participation in another interventional study during this study.\n6. Previous treatment in this study.\n7. Any other reason that, in the opinion of the Investigator, is likely to unfavorably alter subject risk-benefit, confound results, or make it difficult for the subject to fully comply with study requirements.","12 Years",{"count":52,"type":20},100,"INTERVENTIONAL",[55],"PHASE1","The goal of this exploratory study is to evaluate the effects of inhaled epinephrine in subjects, who may not be eligible for the GHL-101 trial, and who are experiencing systemic allergic reaction (SAR) that occur following allergy testing, subcutaneous immunotherapy (SCIT), oral challenges (with food and\u002For drug) or oral immunotherapy (OIT).",[58,25],"Hypersensitivity",[60,61,62,63,58,64,25,65,66,67,68],"Immunotherapy","Epinephrine","Upper airway laryngeal edema","Upper airway pharyngeal edema","Hypersensitivity, immediate","Vasoconstrictor agents","Adrenergic alpha-Agonists","Adrenergic beta-Agonists","Bronchodilator agents","2026-02-03",{"date":71,"type":34},"2026-02-05",{"date":73,"type":34},"2025-08-25",{"date":75,"type":20},"2026-07",{"name":77,"class":41},"Dr. George Luciuk",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":53,"phases":91,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100619219","phase-4-steroid-use-in-treatment-of-allergic-reactions-to-food-100619219","NCT07341776","Steroid Use in Treatment of Allergic Reactions to Food","Evaluation of Emergency Medication in Children With Food Allergies: a Prospective, Randomized Clinical Multicenter Study Comparing Antihistamines Versus Antihistamines Plus Steroids in a Controlled Setting of Oral Food Challenges in Children.","SAFARI","Inclusion Criteria:\n\n* suspected or confirmed IgE-mediated food allergy\n\nExclusion Criteria:\n\n* Non-IgE mediated food allergies\n* Non-food allergies\n* Age outside the specified range\n* Contraindications for an oral food challenge or oral steroid use within one week before the challenge.","6 Months","18 Years",{"count":90,"type":20},160,[92],"PHASE4","In this study, the investigators want to find out whether a specific medication commonly used for severe allergic reactions is really necessary. When children have allergic reactions to foods, they are often given medications to relieve the symptoms. In addition to adrenaline and antihistamines, steroids are frequently administered in German-speaking Switzerland. However, it is unclear whether steroids are really helpful in this situation. To investigate this, the investigators are comparing two groups: one group receives additional steroids, and the other does not. Which treatment a participant receives is decided randomly, like flipping a coin. The study takes place during a pre-scheduled provocation test at the clinic. If an allergic reaction occurs, the usual emergency medications will be administered. Doctors will closely monitor how the reaction develops. No additional tests or visits are required. The results of this study could help improve allergy treatment in the future.",[95,25,96,97],"Anaphylactic Reaction","Allergy in Children","IgE Mediated Food Allergy","2026-01-26",{"date":100,"type":34},"2026-01-27",{"date":98,"type":34},{"date":103,"type":20},"2026-12",{"name":105,"class":41},"Johannes Trueck",2,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":114,"sex":16,"minAge":88,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":78},"100618173","analysis-of-the-role-of-ige-proteoforms-in-health-and-disease-100618173","NCT07328178","Analysis of the Role of IgE Proteoforms in Health and Disease","IgE-PhD","Inclusion Criteria:\n\n* CSU and type I allergic diseases (including anaphylaxis and desensitization), atopic dermatitis, mastocytosis, XLA and HaT (informed consent, age: any available adult subject, gender: any available subject, clinical phenotype and specific information about the allergy (e.g. severity, medication, medical history, laboratory testing)\n* Healthy controls (informed consent, age matched to the allergic patients, gender matched to the allergic patients, patient-reported symptoms related to allergy to aeroallergens, food, drugs, hymenoptera venom, CSU)\n\nExclusion Criteria:\n\n* Absence of informed consent\n* Age \\\u003C 18 years old",true,{"count":116,"type":20},200,"The goal of this observational study is to evaluate the role of IgE proteoforms in healthy volunteers and in patients with type I allergy, patients with chronic spontaneous urticaria, patients with a recent history of anaphylaxis, patients with mastocytosis, patients with hereditary alpha tryptasemia, patients with X-linked agammaglobulinemia (XLA), and patients undergoing desensitization for venom or medication allergy.",[25,119,120,121,122,123,124,125,126],"Mastocytosis","X-linked Agammaglobulinaemia","Venom Allergy","Chronic Spontaneous Urticaria (CSU)","Type I Allergy","Medication Allergy","Healthy Control","Hereditary Alpha-Tryptasemia","2025-12-26",{"date":129,"type":34},"2026-01-09",{"date":131,"type":34},"2025-01-01",{"date":133,"type":20},"2029-01-01",{"name":135,"class":41},"KU Leuven",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":144,"targetDuration":146,"studyType":21,"phases":4,"briefSummary":147,"conditions":148,"keywords":154,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":78},"100412651","a-registry-for-the-food-allergy-community-100412651","NCT04653324","A Registry for the Food Allergy Community","The FARE Patient Registry: A Registry for the Food Allergy Community","FPR","Inclusion Criteria:\n\n* Individuals with diagnosed food allergy\n\nExclusion Criteria:\n\n* Individuals without food allergy",{"count":145,"type":20},23000,"5 Years","The FARE Patient Registry will serve as a prospective, observational food allergy reporting system that stores detailed health and other basic information about patients' real-world experiences with food allergies, to encourage open sharing of de-identified data and participation in clinical trials. The FARE Patient Registry intends to make and support scientific discoveries by enabling the food allergy community to participate directly in research.",[149,25,150,151,152,153],"Food Hypersensitivity","Eosinophilic Esophagitis","Food Sensitivity","Food Intolerance","Food Allergy in Infants",[155],"food allergy","2025-03-10",{"date":158,"type":34},"2025-03-12",{"date":160,"type":34},"2017-08-24",{"date":162,"type":20},"2027-08",{"name":164,"class":41},"Food Allergy Research & Education",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":171,"targetDuration":173,"studyType":21,"phases":4,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":78},"100455437","acquisition-and-long-term-observation-of-patients-with-severe-allergic-reactions-100455437","NCT05210543","Acquisition and Long-term Observation of Patients With Severe Allergic Reactions","Inclusion Criteria:\n\n* Anaphylactic reaction within the past 12 months\n\nExclusion Criteria:\n\n\\-",{"count":172,"type":20},20000,"1 Day","The Anaphylaxis Registry aims to assess data in a standardized form about symptoms, triggers, cofactors and therapy management from patients who experienced an anaphylactic reaction. This should improve diagnosis and long-term management of these life-threatening allergic reactions.",[25],"2024-08-20",{"date":178,"type":34},"2024-08-21",{"date":180,"type":34},"2007-01-01",{"date":182,"type":20},"2030-12",{"name":184,"class":41},"Charite University, Berlin, Germany",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":114,"sex":16,"minAge":191,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":53,"phases":195,"briefSummary":196,"conditions":197,"keywords":198,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":78},"100325915","phase-1-use-of-dexamethasone-in-prevention-of-the-second-phase-or-a-biphasic-reaction-of-anaphylaxis-100325915","NCT03523221","Use of Dexamethasone in Prevention of the Second Phase or a Biphasic Reaction of Anaphylaxis","Inclusion Criteria:\n\n* All patients 3 monthes-14years presenting to the Pediatric Emergency Department (AlSadd) with mild to moderate anaphylaxis\n\nExclusion Criteria:\n\nPatients with severe anaphylaxis. Patient with history of immunological diseases. Patients on steroids therapy Patient with moderate-severe asthma on medication Patients with severe asthma","3 Months","14 Years",{"count":194,"type":20},210,[55],"Anaphylaxis is an acute serious allergic reaction, with multi-organ system manifestations caused by the release of chemical mediators and it is potentially fatal .\n\nBetween 5% and 14% of patients may experience a recurrence of anaphylaxis 8-12 hours after the initial presentation, called biphasic (late-phase) .\n\nThe mainstay of treatment for children experiencing anaphylaxis remains adrenaline and H1-antihistamines. Corticosteroids are not life-saving and do not have an immediate effect on the symptoms of anaphylaxis but may help reduce or prevent a biphasic \"late phase\" reaction .\n\nThe aim of this study is to compare the efficacy of oral glucocorticoids in prevention of the second phase or biphasic reaction of anaphylaxis, as compared to placebo in children, presenting to the pediatric emergency department (PEC Al-Sadd) with mild to moderate anaphylaxis (Prospective Study).\n\nPatients will be randomized to either one of the two treatment:\n\nTreatment 1: Dexamethasone 0.6mg\u002Fkg oral. Treatment 2 : Placebo All patients will be urgently treated for anaphylaxis according to guideline protocol. Enrolled patients will be given one of the study medications orally, and he \u002Fshe will observe in the observation room with cardiac monitor and close monitoring by nurse.\n\nThe treating physician will discharge patient when he\u002Fshe looks well, breathing comfortably, has oxygen saturation \\>94%, stable blood pressure and no gastrointestinal or neurological manifestation.\n\nDischarge patients will be sent home on anti-histamine (cetirizine) for 5days. All patients will be followed up for one week post discharge by a phone call asking about the general condition, relapse of symptoms, or need for readmission.",[25],[199],"Mild -Moderate Anaphylaxis","2024-08-13",{"date":202,"type":34},"2024-08-14",{"date":204,"type":34},"2018-04-15",{"date":206,"type":20},"2024-12",{"name":208,"class":209},"Hamad Medical Corporation","INDUSTRY",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":4,"enrollmentInfo":218,"targetDuration":146,"studyType":21,"phases":4,"briefSummary":220,"conditions":221,"keywords":240,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":78},"100409713","acutelines-a-large-data-biobank-of-acute-and-emergency-medicine-100409713","NCT04615065","Acutelines: a Large Data-\u002FBiobank of Acute and Emergency Medicine","Acutelines: a Large Biobank Aiming to Improve Early Recognition of Acute Diseases, Contribute to the Development of Personalized Medicine and Optimize Short- and Long-term Outcome","Acutelines","Inclusion Criteria, at least one of the following:\n\n* Triaged as one of highest two triage categories (red or orange) according to the Manchester triage system;\n* Triaged as the third highest triage category (yellow) and arrival by EMS of Helicopter Emergency Medical Service (HEMS;\n* Shock\n* Suspicion of sepsis (based on either physicians' suspicion, Sepsis-2 or Sepsis-3 criteria)\n* Acute kidney injury (AKI)\n* Anaphylactic reaction\n* Syncope\n* Intoxication\n* Thrombosis\n* Pulmonary embolism\n* Bleeding while using anti-coagulant drugs\n* Gastro-intestinal bleeding\n* Electrolyte disturbance\n\nExclusion Criteria:\n\n* Referred for organ transplantation as recipient\n* Transfer from other hospital\n* Accidental contact patient material (i.e. internal work-related accident)\n\nWhile data- and imaging will be collected from all these patients, biomaterials will only be collected from patients fulfilling the first criterion (i.e. triaged as one of highest two triage categories \\[red or orange\\] according to the Manchester triage system) and from patients with shock or a suspicion of sepsis.",{"count":219,"type":20},35000,"Research in acute care faces many challenges, including enrollment challenges, legal limitations in data sharing, limited funding, and lack of singular ownership of the domain of acute care. To overcome some of these challenges, the Center of Acute Care of the University Medical Center Groningen in the Netherlands, has established a de novo data-, image- and biobank named \"Acutelines\". Acutelines is initiated to improve recognition and treatment of acute diseases and obtain insight in the consequences of acute diseases, including factors predicting its outcome. Thereby, Acutelines contributes to development of personalized treatment and improves prediction of patient outcomes after an acute admission.",[222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,25,239],"Acute Disease","Sepsis","Pneumonia","Frailty","Complication of Treatment","Pulmonary Embolism","Thrombosis","Acute Kidney Injury","Electrolyte Disturbance","Hemorrhage","Shock","Polypharmacy","Intoxication by Drug","Emergencies","Urinary Tract Infections","Skin Infection","Syncope","Dyspnea",[241,223,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262],"Acute disease","Emergency Medical Service (EMS)","Outcome","Precision medicine","Personalized medicine","Emergency medicine","Multidisciplinary","General practitionar","Pharmacy","Hospitalization","Health insurance","Mortality","Quality of life (QoL)","Overcrowding","Patient logistics","Point-of-care ultrasound (POCUS)","Helicopter Emergency Medical Service (HEMS)","Biobank","Databank","Electrophysiological waveforms","Electrocardiogram (ECG)","Plethysmogram","2024-06-12",{"date":265,"type":34},"2024-06-13",{"date":267,"type":34},"2020-09-01",{"date":269,"type":20},"2030-09-01",{"name":271,"class":41},"University Medical Center Groningen"]